Table. 3.

Heart transplantation cases

Case Type of cancer Allograft outcome Checkpoint inhibitor Year from tx to ICI IS regimen Cancer response Interval between IS reduction and ICI initiation ICI to rejection time
Daud et al. (2020) [82] Melanoma Rejected Pembrolizumab 18 Tac+azathioprine NA NA Within 3 mo
LUAC Rejected Pembrolizumab 16 CYA, MMF, everolimus/sirolimus, Pred NA NA Within 3 mo
Melanoma Rejected Nivolumab 24 CYA, MMF, Pred NA NA Within 3 mo
Melanoma No rejection Pembrolizumab 19 Tac NA NA
Grant et al. (2018) [83] Melanoma No rejection Pembrolizumab 8 Tac+MMF PD NA
Kittai et al. (2017) [30] LUSC No rejection Nivolumab 10 CYA+MMF+Pred → CYA+MMF SD NA
Owonikoko et al. (2017) [84] cSCC Rejected Nivolumab 19 Tac+sirolimus+Pred → Tac+Pred NA NA 5 day
Gastman et al. (2016) [85] Melanoma No rejection Ipilimumab×4 15 Tac+MMF+Pred → Tac+Pred SD NA
Qin et al. (2015) [86] Melanoma No rejection Ipilimumab×4 12 Tac PD NA

tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; Tac, tacrolimus; NA, not applicable; LUAC, lung adenocarcinoma; CYA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; PD, progressive disease; LUSC, lung squamous cell carcinoma; SD, stable disease; cSCC, cutaneous squamous cell carcinoma.

Korean J Transplant 2022;36:82~98 https://doi.org/10.4285/kjt.22.0013
© Korean Journal of Transplantation